schliessen

Filtern

 

Bibliotheken

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

Background: Topotecan has been shown in previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription. Purpose: Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, a... Full description

Journal Title: Journal of the National Cancer Institute Sept 15, 1993, Vol.85(18), p.1499(9)
Main Author: Saltz, Leonard
Other Authors: Sirott, Matthew , Young, Charles , Tong, William , Niedzwiecki, Donna , Tzy - Jyun Yao , Tao Yue , Trochanowski, Bonnie , Wright, Patricia , Barbosa, Karen , Toomasi, Frieda , Kelsen, David
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0027-8874
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: gale_ofa14227837
title: Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
format: Article
creator:
  • Saltz, Leonard
  • Sirott, Matthew
  • Young, Charles
  • Tong, William
  • Niedzwiecki, Donna
  • Tzy - Jyun Yao
  • Tao Yue
  • Trochanowski, Bonnie
  • Wright, Patricia
  • Barbosa, Karen
  • Toomasi, Frieda
  • Kelsen, David
subjects:
  • Alkaloids -- Physiological Aspects
  • Antineoplastic Agents -- Testing
  • Granulocyte Colony-stimulating Factor -- Health Aspects
ispartof: Journal of the National Cancer Institute, Sept 15, 1993, Vol.85(18), p.1499(9)
description: Background: Topotecan has been shown in previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription. Purpose: Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, and recommended phase II dose of topotecan and to define the pharmacokinetics of topotecan in humans. Methods: Forty-three patients with advanced, incurable solid tumors were treated. Doses ranged from 0.5 to 2.0 mg/[m.sup.2] daily, with treatment cycles repeated initially every 28 days. Following the identification of the standard maximum tolerated dose, further dose escalations were attempted by following topotecan cycles with recombinant granulocyte colony-stimulating factor (rG-CSF). Results: The maximum tolerated dose without rG-CSF for patients without prior cytotoxic therapy was 1.75 mg/[m.sup.2] daily. The maximum tolerated dose for previously treated patients was 1.50 mg/[m.sup.2] daily. The dose-limiting toxic effect was myelosuppression, with granulocytopenia being most commonly observed. Use of rG-CSF did not permit topotecan dose intensification, since thrombocytopenia and fatigue rapidly emerged as dose-limiting toxic effects. Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively. Conclusions: The doses of topotecan recommended for use in phase II clinical trials in solid tumors are 1.5 and 1.25 mg/[m.sup.2] daily in previously untreated and previously treated patients, respectively. Based on observed rates of recovery from myelosuppression, treatment should be possible on a 21-day cycle. Dose intensification was not possible with the use of rG-CSF; however, rG-CSF may be a useful addition to the regimens of those few patients who experience either prolonged granulocytopenia or neutropenic sepsis or those who are not able to receive their second treatment cycle by day 21. [J Natl Cancer Inst 85:1499-1507, 1993]
language:
source:
identifier: ISSN: 0027-8874
fulltext: fulltext
issn:
  • 0027-8874
  • 00278874
url: Link


@attributes
ID1171899886
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid14227837
sourceidgale_ofa
recordidTN_gale_ofa14227837
sourceformatXML
sourcesystemPC
pqid235577527
galeid14227837
display
typearticle
titlePhase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
creatorSaltz, Leonard ; Sirott, Matthew ; Young, Charles ; Tong, William ; Niedzwiecki, Donna ; Tzy - Jyun Yao ; Tao Yue ; Trochanowski, Bonnie ; Wright, Patricia ; Barbosa, Karen ; Toomasi, Frieda ; Kelsen, David
ispartofJournal of the National Cancer Institute, Sept 15, 1993, Vol.85(18), p.1499(9)
identifierISSN: 0027-8874
subjectAlkaloids -- Physiological Aspects ; Antineoplastic Agents -- Testing ; Granulocyte Colony-stimulating Factor -- Health Aspects
descriptionBackground: Topotecan has been shown in previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription. Purpose: Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, and recommended phase II dose of topotecan and to define the pharmacokinetics of topotecan in humans. Methods: Forty-three patients with advanced, incurable solid tumors were treated. Doses ranged from 0.5 to 2.0 mg/[m.sup.2] daily, with treatment cycles repeated initially every 28 days. Following the identification of the standard maximum tolerated dose, further dose escalations were attempted by following topotecan cycles with recombinant granulocyte colony-stimulating factor (rG-CSF). Results: The maximum tolerated dose without rG-CSF for patients without prior cytotoxic therapy was 1.75 mg/[m.sup.2] daily. The maximum tolerated dose for previously treated patients was 1.50 mg/[m.sup.2] daily. The dose-limiting toxic effect was myelosuppression, with granulocytopenia being most commonly observed. Use of rG-CSF did not permit topotecan dose intensification, since thrombocytopenia and fatigue rapidly emerged as dose-limiting toxic effects. Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively. Conclusions: The doses of topotecan recommended for use in phase II clinical trials in solid tumors are 1.5 and 1.25 mg/[m.sup.2] daily in previously untreated and previously treated patients, respectively. Based on observed rates of recovery from myelosuppression, treatment should be possible on a 21-day cycle. Dose intensification was not possible with the use of rG-CSF; however, rG-CSF may be a useful addition to the regimens of those few patients who experience either prolonged granulocytopenia or neutropenic sepsis or those who are not able to receive their second treatment cycle by day 21. [J Natl Cancer Inst 85:1499-1507, 1993]
source
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
scope
0gale_onefileg
1gale_onefilea
2OneFile
creatorcontrib
0Saltz, Leonard
1Sirott, Matthew
2Young, Charles
3Tong, William
4Niedzwiecki, Donna
5Tzy-Jyun Yao
6Tao Yue
7Trochanowski, Bonnie
8Wright, Patricia
9Barbosa, Karen
10Toomasi, Frieda
11Kelsen, David
titlePhase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
descriptionBackground: Topotecan has been shown in previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription. Purpose: Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, and recommended phase II dose of topotecan and to define the pharmacokinetics of topotecan in humans. Methods: Forty-three patients with advanced, incurable solid tumors were treated. Doses ranged from 0.5 to 2.0 mg/[m.sup.2] daily, with treatment cycles repeated initially every 28 days. Following the identification of the standard maximum tolerated dose, further dose escalations were attempted by following topotecan cycles with recombinant granulocyte colony-stimulating factor (rG-CSF). Results: The maximum tolerated dose without rG-CSF for patients without prior cytotoxic therapy was 1.75 mg/[m.sup.2] daily. The maximum tolerated dose for previously treated patients was 1.50 mg/[m.sup.2] daily. The dose-limiting toxic effect was myelosuppression, with granulocytopenia being most commonly observed. Use of rG-CSF did not permit topotecan dose intensification, since thrombocytopenia and fatigue rapidly emerged as dose-limiting toxic effects. Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively. Conclusions: The doses of topotecan recommended for use in phase II clinical trials in solid tumors are 1.5 and 1.25 mg/[m.sup.2] daily in previously untreated and previously treated patients, respectively. Based on observed rates of recovery from myelosuppression, treatment should be possible on a 21-day cycle. Dose intensification was not possible with the use of rG-CSF; however, rG-CSF may be a useful addition to the regimens of those few patients who experience either prolonged granulocytopenia or neutropenic sepsis or those who are not able to receive their second treatment cycle by day 21. [J Natl Cancer Inst 85:1499-1507, 1993]
subject
0Alkaloids--Physiological aspects
1Antineoplastic agents--Testing
2Granulocyte colony-stimulating factor--Health aspects
general
0U.S. National Cancer Institute
1Cengage Learning, Inc.
sourceidgale_ofa
recordidgale_ofa14227837
issn
00027-8874
100278874
rsrctypearticle
creationdate1993
recordtypearticle
addtitleJournal of the National Cancer Institute
searchscopeOneFile
lsr30VSR-Enriched:[doi, pqid, galeid, pages, eissn]
sort
titlePhase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
authorSaltz, Leonard ; Sirott, Matthew ; Young, Charles ; Tong, William ; Niedzwiecki, Donna ; Tzy - Jyun Yao ; Tao Yue ; Trochanowski, Bonnie ; Wright, Patricia ; Barbosa, Karen ; Toomasi, Frieda ; Kelsen, David
creationdate19930915
facets
frbrgroupid3663525163265877428
frbrtype5
creationdate1993
topic
0Alkaloids–Physiological Aspects
1Antineoplastic Agents–Testing
2Granulocyte Colony-stimulating Factor–Health Aspects
collectionOneFile (GALE)
prefilterarticles
rsrctypearticles
creatorcontrib
0Saltz, Leonard
1Sirott, Matthew
2Young, Charles
3Tong, William
4Niedzwiecki, Donna
5Tzy - Jyun Yao
6Tao Yue
7Trochanowski, Bonnie
8Wright, Patricia
9Barbosa, Karen
10Toomasi, Frieda
11Kelsen, David
jtitleJournal of the National Cancer Institute
toplevelpeer_reviewed
frbr
t2
k11993
k200278874
k485
k518
k61499
k7journal of the national cancer institute
k8phase clinical pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors with attempt at dose intensification using recombinant granulocyte colony stimulating factor
k9phaseiclinicalandphaactor
k12phaseiclinicalandpharmaco
k15leonardsaltz
k16saltzleonard
delivery
delcategoryRemote Search Resource
fulltextfulltext
ranking
booster11
booster21
pcg_typeaggregator
addata
au
0Saltz, Leonard
1Sirott, Matthew
2Young, Charles
3Tong, William
4Niedzwiecki, Donna
5Tzy-Jyun Yao
6Tao Yue
7Trochanowski, Bonnie
8Wright, Patricia
9Barbosa, Karen
10Toomasi, Frieda
11Kelsen, David
atitlePhase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
jtitleJournal of the National Cancer Institute
risdate19930915
volume85
issue18
spage1499
issn0027-8874
genrearticle
ristypeJOUR
abstractBackground: Topotecan has been shown in previous studies to be a specific inhibitor of topoisomerase I, a nuclear enzyme required for DNA replication and transcription. Purpose: Our objectives in this phase I clinical trial were to determine the maximum tolerated dose, dose-limiting toxic effects, and recommended phase II dose of topotecan and to define the pharmacokinetics of topotecan in humans. Methods: Forty-three patients with advanced, incurable solid tumors were treated. Doses ranged from 0.5 to 2.0 mg/[m.sup.2] daily, with treatment cycles repeated initially every 28 days. Following the identification of the standard maximum tolerated dose, further dose escalations were attempted by following topotecan cycles with recombinant granulocyte colony-stimulating factor (rG-CSF). Results: The maximum tolerated dose without rG-CSF for patients without prior cytotoxic therapy was 1.75 mg/[m.sup.2] daily. The maximum tolerated dose for previously treated patients was 1.50 mg/[m.sup.2] daily. The dose-limiting toxic effect was myelosuppression, with granulocytopenia being most commonly observed. Use of rG-CSF did not permit topotecan dose intensification, since thrombocytopenia and fatigue rapidly emerged as dose-limiting toxic effects. Plasma half-lives of topotecan (lactone form) were approximately 10 and 100 minutes for distribution and elimination phases, respectively. Conclusions: The doses of topotecan recommended for use in phase II clinical trials in solid tumors are 1.5 and 1.25 mg/[m.sup.2] daily in previously untreated and previously treated patients, respectively. Based on observed rates of recovery from myelosuppression, treatment should be possible on a 21-day cycle. Dose intensification was not possible with the use of rG-CSF; however, rG-CSF may be a useful addition to the regimens of those few patients who experience either prolonged granulocytopenia or neutropenic sepsis or those who are not able to receive their second treatment cycle by day 21. [J Natl Cancer Inst 85:1499-1507, 1993]
pubU.S. National Cancer Institute
lad01gale_ofa
doi10.1093/jnci/85.18.1499
pages1499-1507
eissn14602105
date1993-09-15